{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:19:49Z","timestamp":1788981589168,"version":"build-2803163510"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13318-026-01019-9","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:31:35Z","timestamp":1782455495000},"page":"485-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics of Amikacin in Non-Neonatal Pediatric Patients: A Scoping Review"],"prefix":"10.1007","volume":"51","author":[{"given":"Chin Chiang","family":"Toh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Makmor Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noraida","family":"Mohamed Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6243-6975","authenticated-orcid":false,"given":"Shamin","family":"Mohd Saffian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"1019_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22122267","author":"MS Ramirez","year":"2017","unstructured":"Ramirez MS, Tolmasky ME. Amikacin: uses, resistance, and prospects for inhibition. Molecules. 2017. https:\/\/doi.org\/10.3390\/molecules22122267.","journal-title":"Molecules"},{"key":"1019_CR2","doi-asserted-by":"publisher","DOI":"10.1128\/ecosalplus.ESP-0002-2018","author":"AW Serio","year":"2018","unstructured":"Serio AW, Keepers T, Andrews L, Krause KM. Aminoglycoside revival: review of a historically important class of antimicrobials undergoing rejuvenation. EcoSal Plus. 2018. https:\/\/doi.org\/10.1128\/ecosalplus.ESP-0002-2018.","journal-title":"EcoSal Plus"},{"issue":"6","key":"1019_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/0897190014546102","volume":"27","author":"CJ Destache","year":"2014","unstructured":"Destache CJ. Aminoglycoside-induced nephrotoxicity\u2014A focus on monitoring: a review of literature. J Pharm Pract. 2014;27(6):562\u20136. https:\/\/doi.org\/10.1177\/0897190014546102.","journal-title":"J Pharm Pract"},{"key":"1019_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101353","author":"S Rivetti","year":"2023","unstructured":"Rivetti S, Romano A, Mastrangelo S, Attin\u00e0 G, Maurizi P, Ruggiero A. Aminoglycosides-related ototoxicity: mechanisms, risk factors, and prevention in pediatric patients. Pharmaceuticals. 2023. https:\/\/doi.org\/10.3390\/ph16101353.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1019_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","volume":"155","author":"RD Moore","year":"1987","unstructured":"Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93\u20139. https:\/\/doi.org\/10.1093\/infdis\/155.1.93.","journal-title":"J Infect Dis"},{"issue":"1","key":"1019_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","volume":"73","author":"JA Roberts","year":"2012","unstructured":"Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012;73(1):27\u201336. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04080.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1019_CR7","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/phar.2193","volume":"38","author":"CM Bland","year":"2018","unstructured":"Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. Pharmacotherapy. 2018;38(12):1229\u201338. https:\/\/doi.org\/10.1002\/phar.2193.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1019_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijantimicag.2013.04.021","volume":"42","author":"H Zazo","year":"2013","unstructured":"Zazo H, Martin-Suarez A, Lanao JM. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic\/pharmacodynamic analysis using Monte Carlo simulation. Int J Antimicrob Agents. 2013;42(2):155\u201360. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.04.021.","journal-title":"Int J Antimicrob Agents"},{"key":"1019_CR9","doi-asserted-by":"publisher","unstructured":"Salehifar E, Rafati MR. Extended-interval dosing of aminoglycosides in pediatrics: a narrative review. J Pediatr Rev. 2015. https:\/\/doi.org\/10.17795\/jpr-2652.","DOI":"10.17795\/jpr-2652"},{"key":"1019_CR10","doi-asserted-by":"publisher","unstructured":"Pacifici GM, Marchini G. Clinical Pharmacology of amikacin in infants and children. Clin Med Invest. 2019. https:\/\/doi.org\/10.15761\/cmi.1000199.","DOI":"10.15761\/cmi.1000199"},{"key":"1019_CR11","doi-asserted-by":"publisher","unstructured":"Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, JP. I. Extended-interval aminoglycoside administration for children a meta-analysis. Pediatics. 2004;114(1):e111\u20138. https:\/\/doi.org\/10.1542\/peds.114.1.e111.","DOI":"10.1542\/peds.114.1.e111"},{"issue":"10","key":"1019_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40262-018-0641-x","volume":"57","author":"SM Illamola","year":"2018","unstructured":"Illamola SM, Sherwin CM, van Hasselt JGC. Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses. Clin Pharmacokinet. 2018;57(10):1217\u201328. https:\/\/doi.org\/10.1007\/s40262-018-0641-x.","journal-title":"Clin Pharmacokinet"},{"key":"1019_CR13","doi-asserted-by":"publisher","unstructured":"Chandrasekar K, Navaswetha T, Vasudevan H, Kumar SN, Arun KP. Review on population pharmacokinetics of amikacin in paediatrics. J Pure Appl Microbiol. 2022;16(4):2303\u20139. https:\/\/doi.org\/10.22207\/jpam.16.4.20.","DOI":"10.22207\/jpam.16.4.20"},{"issue":"1","key":"1019_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-024-01459-z","volume":"64","author":"M Albanell-Fern\u00e1ndez","year":"2025","unstructured":"Albanell-Fern\u00e1ndez M, Rodr\u00edguez-Reyes M, Bastida C, Soy D. A review of vancomycin, gentamicin, and amikacin population pharmacokinetic models in neonates and infants. Clin Pharmacokinet. 2025;64(1):1\u201325. https:\/\/doi.org\/10.1007\/s40262-024-01459-z.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1019_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometr Syst Pharmacol. 2012;1(9):e6. https:\/\/doi.org\/10.1038\/psp.2012.4.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"12","key":"1019_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367. https:\/\/doi.org\/10.1056\/NEJMra035092.","journal-title":"N Engl J Med"},{"key":"1019_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et\u00a0al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"2","key":"1019_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40262-013-0114-1","volume":"53","author":"KM Jamsen","year":"2014","unstructured":"Jamsen KM, McLeay SC, Barras MA, Green B. Reporting a population pharmacokinetic-pharmacodynamic study: a journal\u2019s perspective. Clin Pharmacokinet. 2014;53(2):111\u201322. https:\/\/doi.org\/10.1007\/s40262-013-0114-1.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1019_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et\u00a0al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783\u201395. https:\/\/doi.org\/10.1007\/s40262-015-0236-8.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1019_CR20","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00228-022-03362-7","volume":"78","author":"L Thomas","year":"2022","unstructured":"Thomas L, Raju AP, Chaithra MSS, Varma M, Saravu K, et\u00a0al. Influence of N-acetyltransferase 2 (NAT2) genotype\/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models. Eur J Clin Pharmacol. 2022;78(10):1535\u201353. https:\/\/doi.org\/10.1007\/s00228-022-03362-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1019_CR21","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1111\/bcp.15298","volume":"88","author":"MR Muda","year":"2022","unstructured":"Muda MR, Harun SN, Syed Sulaiman SA, Sheikh Ghadzi SM. Population pharmacokinetics analyses of rifampicin in adult and children populations: a systematic review. Br J Clin Pharmacol. 2022;88(7):3132\u201352. https:\/\/doi.org\/10.1111\/bcp.15298.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1019_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/17512433.2021.1917377","volume":"14","author":"YT Chen","year":"2021","unstructured":"Chen YT, Wang CY, Yin YW, Li ZR, Lin WW, Zhu M, et\u00a0al. Population pharmacokinetics of oxcarbazepine: a systematic review. Expert Rev Clin Pharmacol. 2021;14(7):853\u201364. https:\/\/doi.org\/10.1080\/17512433.2021.1917377.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"1019_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/biology12010051","volume":"12","author":"JS Dilli Batcha","year":"2022","unstructured":"Dilli Batcha JS, Raju AP, Matcha S, Raj SE, Udupa KS, Gota V, et\u00a0al. Factors influencing pharmacokinetics of tamoxifen in breast cancer patients: a systematic review of population pharmacokinetic models. Biology (Basel). 2022;12(1):51. https:\/\/doi.org\/10.3390\/biology12010051.","journal-title":"Biology (Basel)."},{"issue":"6","key":"1019_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/pharmaceutics16060819","volume":"16","author":"N Xu","year":"2024","unstructured":"Xu N, Shi Y, Wang Y, Mak W, Yang W, Ng KW, et\u00a0al. Development and quality control of a population pharmacokinetic model library for caspofungin. Pharmaceutics. 2024;16(6):819. https:\/\/doi.org\/10.3390\/pharmaceutics16060819.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1019_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01781-17","volume":"62","author":"AA Alhadab","year":"2018","unstructured":"Alhadab AA, Ahmed MA, Brundage RC. Amikacin pharmacokinetic-pharmacodynamic analysis in pediatric cancer patients. Antimicrob Agents Chemother. 2018;62(4):10\u2013128. https:\/\/doi.org\/10.1128\/AAC.01781-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1019_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/FTD.0000000000000568","volume":"41","author":"XX Liu","year":"2019","unstructured":"Liu XX, Smits A, Wang YH, Renard M, Wead S, Kagan RJ, et\u00a0al. Impact of disease on amikacin pharmacokinetics and dosing in children. Ther Drug Monit. 2019;41(1):44\u201352. https:\/\/doi.org\/10.1097\/FTD.0000000000000568.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1019_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/10601330802383441","volume":"25","author":"RB Akondi","year":"2008","unstructured":"Akondi RB, Chodavarapu RK, Devarakonda KR. Population pharmacokinetics of amikacin in Indian pediatric patients. Clin Res Regul Aff. 2008;25(3):173\u201382. https:\/\/doi.org\/10.1080\/10601330802383441.","journal-title":"Clin Res Regul Aff"},{"issue":"4","key":"1019_CR28","doi-asserted-by":"publisher","first-page":"E244","DOI":"10.1097\/BCR.0000000000000159","volume":"36","author":"T Yu","year":"2015","unstructured":"Yu T, Stockmann C, Healy DP, Olson J, Wead S, Neely AN, et\u00a0al. Determination of optimal amikacin dosing regimens for pediatric patients with burn wound sepsis. J Burn Care Res. 2015;36(4):E244\u201352. https:\/\/doi.org\/10.1097\/BCR.0000000000000159.","journal-title":"J Burn Care Res"},{"issue":"4","key":"1019_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/FTD.0000000000000855","volume":"43","author":"JB Woillard","year":"2021","unstructured":"Woillard JB, Bouchet S, Fayon M, Marquet P, Monchaud C, Bui S. A population pharmacokinetic modeling approach to determine the efficacy of intravenous amikacin in children with cystic fibrosis. Ther Drug Monit. 2021;43(4):499\u2013504. https:\/\/doi.org\/10.1097\/FTD.0000000000000855.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1019_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40272-018-0288-y","volume":"20","author":"S Alqahtani","year":"2018","unstructured":"Alqahtani S, Abouelkheir M, Alsultan A, Elsharawy Y, Alkoraishi A, Osman R, et\u00a0al. Optimizing amikacin dosage in pediatrics based on population pharmacokinetic\/pharmacodynamic modeling. Pediatr Drugs. 2018;20(3):265\u201372. https:\/\/doi.org\/10.1007\/s40272-018-0288-y.","journal-title":"Pediatr Drugs"},{"issue":"2","key":"1019_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.burns.2013.06.015","volume":"40","author":"CM Sherwin","year":"2014","unstructured":"Sherwin CM, Wead S, Stockmann C, Healy D, Spigarelli MG, Neely A, et\u00a0al. Amikacin population pharmacokinetics among paediatric burn patients. Burns. 2014;40(2):311\u20138. https:\/\/doi.org\/10.1016\/j.burns.2013.06.015.","journal-title":"Burns"},{"issue":"11","key":"1019_CR32","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/ppul.24468","volume":"54","author":"P Caceres Guido","year":"2019","unstructured":"Caceres Guido P, Perez M, Halac A, Ferrari M, Ibarra M, Licciardone N, et\u00a0al. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis. Pediatr Pulmonol. 2019;54(11):1801\u201310. https:\/\/doi.org\/10.1002\/ppul.24468.","journal-title":"Pediatr Pulmonol"},{"key":"1019_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"1019_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jcph.1993","volume":"62","author":"S Goutelle","year":"2022","unstructured":"Goutelle S, Woillard JB, Buclin T, Bourguignon L, Yamada W, Csajka C, et\u00a0al. Parametric and nonparametric methods in population pharmacokinetics: experts\u2019 discussion on use, strengths, and limitations. J Clin Pharmacol. 2022;62(2):158\u201370. https:\/\/doi.org\/10.1002\/jcph.1993.","journal-title":"J Clin Pharmacol"},{"key":"1019_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-9485-1","volume-title":"Pharmacokinetic-pharmacodynamic modeling and simulation","author":"P Bonate","year":"2011","unstructured":"Bonate P. Pharmacokinetic-pharmacodynamic modeling and simulation. 2nd ed. Springer; 2011.","edition":"2"},{"issue":"4","key":"1019_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","volume":"34","author":"MN Neely","year":"2012","unstructured":"Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34(4):467\u201376. https:\/\/doi.org\/10.1097\/FTD.0b013e31825c4ba6.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"1019_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.02629-20","volume":"65","author":"SN Avedissian","year":"2021","unstructured":"Avedissian SN, Rohani R, Bradley J, Le J, Rhodes NJ. Optimizing aminoglycoside dosing regimens for critically ill pediatric patients with augmented renal clearance: a convergence of parametric and nonparametric population approaches. Antimicrob Agents Chemother. 2021;65(4):10\u2013128. https:\/\/doi.org\/10.1128\/AAC.02629-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1019_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00993-19","volume":"63","author":"C Boidin","year":"2019","unstructured":"Boidin C, Bourguignon L, Cohen S, Roger C, Lefrant JY, Roberts JA, et\u00a0al. Amikacin initial dose in critically ill patients: a nonparametric approach to optimize a priori pharmacokinetic\/pharmacodynamic target attainments in individual patients. Antimicrob Agents Chemother. 2019;63(11):10\u20131128. https:\/\/doi.org\/10.1128\/AAC.00993-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1019_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40262-016-0428-x","volume":"56","author":"A Marsot","year":"2017","unstructured":"Marsot A, Guilhaumou R, Riff C, Blin O. Amikacin in critically ill patients: a review of population pharmacokinetic studies. Clin Pharmacokinet. 2017;56(2):127\u201338. https:\/\/doi.org\/10.1007\/s40262-016-0428-x.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1019_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2125.2009.03591.x","volume":"70","author":"M Cella","year":"2010","unstructured":"Cella M, Knibbe C, Danhof M, Della PO. What is the right dose for children? Br J Clin Pharmacol. 2010;70(4):597\u2013603. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03591.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1019_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13052-021-01114-4","volume":"47","author":"RH Ghoneim","year":"2021","unstructured":"Ghoneim RH, Thabit AK, Lashkar MO, Ali AS. Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation. Ital J Pediatr. 2021;47(1):167. https:\/\/doi.org\/10.1186\/s13052-021-01114-4.","journal-title":"Ital J Pediatr"},{"issue":"2","key":"1019_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/11595640-000000000-00000","volume":"51","author":"RF De Cock","year":"2012","unstructured":"De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, et\u00a0al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51(2):105\u201317. https:\/\/doi.org\/10.2165\/11595640-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1019_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2174\/187231208786734157","volume":"2","author":"K Allegaert","year":"2008","unstructured":"Allegaert K, Scheers I, Cossey V, Anderson BJ. Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability. Drug Metab Lett. 2008;2(4):286\u20139. https:\/\/doi.org\/10.2174\/187231208786734157.","journal-title":"Drug Metab Lett"},{"issue":"3","key":"1019_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/bcp.13016","volume":"82","author":"SM Illamola","year":"2016","unstructured":"Illamola SM, Colom H, van Hasselt JG. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Br J Clin Pharmacol. 2016;82(3):793\u2013805. https:\/\/doi.org\/10.1111\/bcp.13016.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1019_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00228-009-0637-4","volume":"65","author":"CM Sherwin","year":"2009","unstructured":"Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM. Individualised dosing of amikacin in neonates: a pharmacokinetic\/pharmacodynamic analysis. Eur J Clin Pharmacol. 2009;65(7):705\u201313. https:\/\/doi.org\/10.1007\/s00228-009-0637-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"SUPPL","key":"1019_CR46","doi-asserted-by":"publisher","first-page":"S312","DOI":"10.1093\/infdis\/135.supplement_2.s312","volume":"134","author":"WM Kirby","year":"1976","unstructured":"Kirby WM, Clarke JT, Libke RD, Regamey C. Clinical pharmacology of amikacin and kanamycin. J Infect Dis. 1976;134(SUPPL):S312\u20135. https:\/\/doi.org\/10.1093\/infdis\/135.supplement_2.s312.","journal-title":"J Infect Dis"},{"issue":"2","key":"1019_CR47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/antibiotics10020100","volume":"10","author":"H Kato","year":"2021","unstructured":"Kato H, Parker SL, Roberts JA, Hagihara M, Asai N, Yamagishi Y, et\u00a0al. Population pharmacokinetics analysis of amikacin initial dosing regimen in elderly patients. Antibiotics (Basel). 2021;10(2):100. https:\/\/doi.org\/10.3390\/antibiotics10020100.","journal-title":"Antibiotics (Basel)."},{"issue":"8","key":"1019_CR48","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1093\/jac\/dkaa158","volume":"75","author":"JS Perez-Blanco","year":"2020","unstructured":"Perez-Blanco JS, Saez Fernandez EM, Calvo MV, Lanao JM, Martin-Suarez A. Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach. J Antimicrob Chemother. 2020;75(8):2222\u201331. https:\/\/doi.org\/10.1093\/jac\/dkaa158.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1019_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.02178-19","volume":"64","author":"NA Arechiga-Alvarado","year":"2020","unstructured":"Arechiga-Alvarado NA, Medellin-Garibay SE, Milan-Segovia RDC, Ortiz-Alvarez A, Magana-Aquino M, Romano-Moreno S. Population pharmacokinetics of amikacin administered once daily in patients with different renal functions. Antimicrob Agents Chemother. 2020;64(5):10\u2013128. https:\/\/doi.org\/10.1128\/AAC.02178-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1019_CR50","unstructured":"NJ Walker, King K. Acute and chronic thermal burn evaluation and management. . InStatPearls [Internet]. StatPearls Publishing; 2023."},{"issue":"1","key":"1019_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/sur.2020.375","volume":"22","author":"KA Pruskowski","year":"2021","unstructured":"Pruskowski KA. Pharmacokinetics and pharmacodynamics of antimicrobial agents in burn patients. Surg Infect (Larchmt). 2021;22(1):77\u201382. https:\/\/doi.org\/10.1089\/sur.2020.375.","journal-title":"Surg Infect (Larchmt)"},{"key":"1019_CR52","doi-asserted-by":"publisher","first-page":"723731","DOI":"10.3389\/fphar.2021.723731","volume":"12","author":"Y Luo","year":"2021","unstructured":"Luo Y, Wang Y, Ma Y, Wang P, Zhong J, Chu Y. Augmented renal clearance: what have we known and what will we do? Front Pharmacol. 2021;12:723731. https:\/\/doi.org\/10.3389\/fphar.2021.723731.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1019_CR53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","volume":"14","author":"AM Cantin","year":"2015","unstructured":"Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros. 2015;14(4):419\u201330. https:\/\/doi.org\/10.1016\/j.jcf.2015.03.003.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"1019_CR54","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00467-010-1737-1","volume":"26","author":"C Prestidge","year":"2011","unstructured":"Prestidge C, Chilvers MA, Davidson AG, Cho E, McMahon V, White CT. Renal function in pediatric cystic fibrosis patients in the first decade of life. Pediatr Nephrol. 2011;26(4):605\u201312. https:\/\/doi.org\/10.1007\/s00467-010-1737-1.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1019_CR55","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/ppul.24689","volume":"55","author":"DJG Thirion","year":"2020","unstructured":"Thirion DJG, Pasche V, Matouk E, Marsot A. Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. Pediatr Pulmonol. 2020;55(5):1154\u201360. https:\/\/doi.org\/10.1002\/ppul.24689.","journal-title":"Pediatr Pulmonol"},{"key":"1019_CR56","doi-asserted-by":"publisher","DOI":"10.1177\/2333794X16635464","author":"KH Safi","year":"2016","unstructured":"Safi KH, Damiani JM, Sturza J, Nasr SZ. Extended-interval aminoglycoside use in cystic fibrosis exacerbation in children and young adults: a prospective quality improvement project. Glob Pediatr Health. 2016. https:\/\/doi.org\/10.1177\/2333794X16635464.","journal-title":"Glob Pediatr Health."},{"issue":"1","key":"1019_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/17425255.2021.1836157","volume":"17","author":"AM Akkerman-Nijland","year":"2021","unstructured":"Akkerman-Nijland AM, Akkerman OW, Grasmeijer F, Hagedoorn P, Frijlink HW, Rottier BL, et\u00a0al. The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opin Drug Metab Toxicol. 2021;17(1):53\u201368. https:\/\/doi.org\/10.1080\/17425255.2021.1836157.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"1019_CR58","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ekir.2022.02.014","volume":"7","author":"H Izzedine","year":"2022","unstructured":"Izzedine H, Mathian A, Amoura Z, Ng JH, Jhaveri KD. Anticancer drug-induced capillary leak syndrome. Kidney Int Rep. 2022;7(5):945\u201353. https:\/\/doi.org\/10.1016\/j.ekir.2022.02.014.","journal-title":"Kidney Int Rep."},{"issue":"2","key":"1019_CR59","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/antibiotics12020373","volume":"12","author":"M Aquino","year":"2023","unstructured":"Aquino M, Tinoco M, Bicker J, Falcao A, Rocha M, Fortuna A. Therapeutic drug monitoring of amikacin in neutropenic oncology patients. Antibiotics (Basel). 2023;12(2):373. https:\/\/doi.org\/10.3390\/antibiotics12020373.","journal-title":"Antibiotics (Basel)."},{"issue":"1","key":"1019_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40780-025-00425-6","volume":"11","author":"R Tanaka","year":"2025","unstructured":"Tanaka R. Pharmacokinetic variability and significance of therapeutic drug monitoring for broad-spectrum antimicrobials in critically ill patients. J Pharm Health Care Sci. 2025;11(1):21. https:\/\/doi.org\/10.1186\/s40780-025-00425-6.","journal-title":"J Pharm Health Care Sci."},{"key":"1019_CR61","first-page":"114","volume":"31","author":"SY Bukhari","year":"2001","unstructured":"Bukhari SY, Jamshaid M, Mustafa M. Pharmacokinetics of amikacin in febrile neutropenic pediatric patients with acute lymphoblastic leukaemia. Turk J Cancer. 2001;31:114\u201320.","journal-title":"Turk J Cancer."},{"issue":"12","key":"1019_CR62","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/cid\/cis210","volume":"54","author":"U Theuretzbacher","year":"2012","unstructured":"Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis. 2012;54(12):1785\u201392. https:\/\/doi.org\/10.1093\/cid\/cis210.","journal-title":"Clin Infect Dis"},{"key":"1019_CR63","doi-asserted-by":"publisher","unstructured":"Romano S, Fdez de Gatta MM, Calvo MV, Caballero D, Dominguez-Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother. 1999;44(2):235\u201342. https:\/\/doi.org\/10.1093\/jac\/44.2.235.","DOI":"10.1093\/jac\/44.2.235"},{"issue":"3","key":"1019_CR64","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1097\/BCR.0000000000000120","volume":"36","author":"AN Steele","year":"2015","unstructured":"Steele AN, Grimsrud KN, Sen S, Palmieri TL, Greenhalgh DG, Tran NK. Gap analysis of pharmacokinetics and pharmacodynamics in burn patients: a review. J Burn Care Res. 2015;36(3):e194-211. https:\/\/doi.org\/10.1097\/BCR.0000000000000120.","journal-title":"J Burn Care Res"},{"issue":"3","key":"1019_CR65","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","volume":"46","author":"K Brendel","year":"2007","unstructured":"Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, et\u00a0al. Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221\u201334. https:\/\/doi.org\/10.2165\/00003088-200746030-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1019_CR66","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00818-25","volume":"69","author":"CP Lim","year":"2025","unstructured":"Lim CP, Candra SR, Tseng SH, Edison EP, Tan MGS, Yong MHA, et\u00a0al. Externally validated population pharmacokinetics of amikacin and evaluation of dosage regimen based on achieved serum concentrations in neonates. Antimicrob Agents Chemother. 2025;69(8):e0081825. https:\/\/doi.org\/10.1128\/aac.00818-25.","journal-title":"Antimicrob Agents Chemother"},{"key":"1019_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115421","volume":"215","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, et\u00a0al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;215:115421. https:\/\/doi.org\/10.1016\/j.addr.2024.115421.","journal-title":"Adv Drug Deliv Rev"},{"key":"1019_CR68","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fphar.2020.00551","volume":"11","author":"A Frymoyer","year":"2020","unstructured":"Frymoyer A, Schwenk HT, Zorn Y, Bio L, Moss JD, Chasmawala B, et\u00a0al. Model-informed precision dosing of vancomycin in hospitalized children: implementation and adoption at an academic children\u2019s hospital. Front Pharmacol. 2020;11:551. https:\/\/doi.org\/10.3389\/fphar.2020.00551.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1019_CR69","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/cpt.3510","volume":"117","author":"AC Dibbets","year":"2025","unstructured":"Dibbets AC, Koldeweij C, Osinga EP, Scheepers HCJ, de Wildt SN. Barriers and facilitators for bringing model-informed precision dosing to the patient\u2019s bedside: a systematic review. Clin Pharmacol Ther. 2025;117(3):633\u201345. https:\/\/doi.org\/10.1002\/cpt.3510.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1019_CR70","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et\u00a0al. PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1019_CR71","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00467-022-05651-w","volume":"38","author":"NJL Smeets","year":"2023","unstructured":"Smeets NJL, Teunissen EMM, van der Velden K, van der Burgh MJP, Linders DE, Teesselink E, et\u00a0al. Glomerular filtration rate in critically ill neonates and children: creatinine-based estimations versus iohexol-based measurements. Pediatr Nephrol. 2023;38(4):1087\u201397. https:\/\/doi.org\/10.1007\/s00467-022-05651-w.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1019_CR72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/cpt.1991","volume":"109","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Sherwin CM, Gonzalez D, Zhang Q, Khurana M, Fisher J, et\u00a0al. Creatinine-based renal function assessment in pediatric drug development: an analysis using clinical data for renally eliminated drugs. Clin Pharmacol Ther. 2021;109(1):263\u20139. https:\/\/doi.org\/10.1002\/cpt.1991.","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01019-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01019-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01019-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:56:19Z","timestamp":1788980179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01019-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01019-9","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chin Chiang Toh\u00a0designed the study, conducted the literature searches, screened records, extracted and synthesized data, prepared figures\/tables, and drafted the manuscript. Shamin Mohd Saffian, Noraida Mohamed Shah, and Mohd Makmor Bakry screened records, provided methodological input, supervised the work, critically revised the manuscript for important intellectual content, and approved the final version. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}